Overview

Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

Status:
Completed
Trial end date:
2015-04-22
Target enrollment:
Participant gender:
Summary
Determine if atomoxetine is safe and well tolerated by children with fetal alcohol syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
University of Oklahoma
Collaborators:
Eli Lilly and Company
Mark L. Wolraich
Treatments:
Atomoxetine Hydrochloride